5 Best International Stocks to Buy Now

3. argenx SE (NASDAQ:ARGX)

Number of Hedge Fund Holders: 35

argenx SE (NASDAQ:ARGX) is a biotechnology company focused on developing therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. argenx SE (NASDAQ:ARGX) was incorporated in 2008 and is based in Breda, the Netherlands. It is one of the best international stocks to monitor. 

Oppenheimer analyst Leland Gershell initiated coverage of argenx SE (NASDAQ:ARGX) on October 11 with a Perform rating and no price target. The “impressive” early launch of VyVgart, authorized in late 2021 for generalized myasthenia gravis, supports Wall Street’s $3 billion global peak sales prediction in this indication. However, VyVgart “may be best-in-class”, but the anti-FcRn space is “becoming increasingly crowded,” the analyst told investors.

According to Insider Monkey’s data, 35 hedge funds were bullish on argenx SE (NASDAQ:ARGX) at the end of Q2 2022, compared to 31 funds in the last quarter. Kurt Von Emster’s VenBio Select Advisor is the largest stakeholder of the company, with 1.26 million shares worth $479.5 million.

Here is what Artisan Partners specifically said about argenx SE (NASDAQ:ARGX) in its Q2 2022 investor letter:

“argenx SE (NASDAQ:ARGX) is a commercial stage biotechnology company with an approved, first-, and potentially best-in-class therapy (FcRn) for autoimmune diseases. In its first full quarter of sales, Vyvgart meaningfully exceeded consensus sales expectations, indicating strong early market traction. In addition, it released positive phase 3 results for Vyvgart’s use in treating immune thrombocytopenia purpura, a blood disorder characterized by low platelet levels. We believe this second indication could receive FDA approval in early 2023, and the news confirms our thesis that Vyvgart is a “pipeline in a product”—a compelling new molecule which is likely to be safe and effective in numerous rare autoimmune disorders.”